Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.4052W HIGH $27.98
Volume
31.43 K
Value Traded
760.20 K
Short % Float
6.29%
Days to Cover
6.4
+6.4%Week
+7.06%1 Month
-5.86%3 Month
+4.83%6 Month
-39.5%5 Year
-32.62%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.08 B
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
15.17 B
Total Shares
499.40 M
Float Shares
494.51 M
Insiders
1.02%
Institutions
115.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ELAN Catalyst Timeline
Dated clinical, regulatory and corporate events for Elanco Animal Health Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Elanco Animal Health Incorporated
415Total events
10Upcoming
174Tier-1 (high impact)
2017 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Completed 25,000-square-foot manufacturing expansion of Elwood, Kansas site
▲Product LaunchBefrenaApprovedPost-Market
Phased launch of Befrena (tirnovetmab)
canine allergic and atopic dermatitissource ↗
▲Quarterly UpdateCorporate
Elanco reports Q2 2026 financial results and raises full-year guidance
▲Product LaunchPost-Market
Credelio Quattro launched in Australia, Canada, and Japan
broad-spectrum parasiticide for dogssource ↗
▲Product LaunchBefrenaApprovedPost-Market
Befrena shipped to nearly 1,400 U.S. clinics
not specifiedsource ↗
▲FDA ApprovalZenreliaApprovedFDA Decision
Zenrelia treated more than two million itchy dogs worldwide
itchy dogssource ↗
▲Product LaunchPost-Market
Shipping expected to begin within 30 days
Lyme disease and leptospirosis in dogssource ↗
▲FDA ApprovalFDA Decision
USDA approval of TruCan Ultra Lyme-L4
Lyme disease and leptospirosis in dogssource ↗
▲FDA ApprovalFDA Decision
FDA Conditional Approval for Credelio Quattro-CA1 for NWS in dogs
New World screwworm larvae infestations in dogssource ↗
▲Emergency Use AuthorizationCredelioApprovedFDA Decision
FDA Emergency Use Authorization for Credelio for NWS in dogs
New World screwworm larvae infestations in dogssource ↗
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for Credelio CAT for NWS in cats
New World screwworm larvae infestations in catssource ↗
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for Negasunt Powder for NWS in livestock
New World screwworm larvae infestations in livestock and other speciessource ↗
▲FDA ApprovalTanidilFDA Decision
EPA Section 18 Emergency Exemption for Tanidil for NWS in livestock
New World screwworm larvae infestations in livestock and other speciessource ↗
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference presentation
▲Product LaunchBefrenaApprovedPost-Market
Phased launch of Befrena underway
canine allergic and atopic dermatitissource ↗
▲Emergency Use AuthorizationFDA Decision
FDA Emergency Use Authorization for Negasunt Powder for New World screwworm
New World screwworm infestations in livestocksource ↗
▲FDA ApprovalTanidilFDA Decision
EPA Section 18 Emergency Exemption for Tanidil for New World screwworm
New World screwworm infestations in livestocksource ↗
▲Product LaunchPost-Market
Launch of Advantage Collar for Dogs
flea, tick and mosquito protectionsource ↗
▲Product LaunchPost-Market
Credelio Quattro launched in Australia
broad-spectrum parasiticide for dogssource ↗
▲Product LaunchPost-Market
Advantage Collar for Dogs launched in April
flea and tick protection for dogssource ↗
▲Product LaunchBefrenaApprovedPost-Market
Befrena commercialization in U.S. expected in Q2 2026
not specifiedsource ↗
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference fireside chat
●Quarterly UpdateCorporate
Elanco provides full year 2026 guidance: 4%-6% organic constant currency revenue growth, 6%-9% adjusted EBITDA growth
◆Oral PresentationPresentation
Elanco presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Product LaunchBefrenaApprovedPost-Market
Expected launch of Befrena in first half of 2026
canine allergic and atopic dermatitissource ↗
▲FDA ApprovalBefrenaApprovedFDA Decision
USDA approval of Befrena (tirnovetmab)
canine allergic and atopic dermatitissource ↗
▲FDA ApprovalFDA Decision
FDA conditional approval for Credelio Quattro-CA1 for treatment of New World screwworm in dogs
New World screwworm larvae infestations in dogssource ↗
▲Other Regulator MilestoneEx-US Regulatory
USDA granted accelerated pathway for conditional approval of novel immuno-therapeutic
◆Other Regulator MilestoneBefrenaApprovedEx-US Regulatory
Final administrative review underway for Befrena approval at USDA
canine atopic dermatitissource ↗
▼Restructuring LayoffsCorporate
Elanco to eliminate 300 positions and shift 300 roles as part of Elanco Ascend program
▲Accelerated Approval PathwayDesignation
USDA granted accelerated pathway for conditional approval of novel immuno-therapeutic
pet health (immuno-therapeutic)source ↗
◆FDA ApprovalBefrenaApprovedFDA Decision
Final administrative review underway for Befrena approval; label alignment complete
canine atopic dermatitis, allergic dermatitissource ↗
◆Oral PresentationPresentation
Elanco management to participate in fireside chat at Piper Sandler 37th Annual Healthcare Conference
◆Oral PresentationPresentation
Elanco management to participate in fireside chat at 8th Annual Evercore Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How ELAN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Elanco Animal Health Incorporated is not a drug developer. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ELAN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bettington Timothy JOfficer (SEE REMARKS) | Sell | -4,350 138,911 held | $23.00 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ELAN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 0.4 % (-20 %) | 4.24 M | 172.49 K | -16.8% ( -34.82 K) |
Ownership Trends
ELAN Short Interest
Shares sold short, counted twice a month.
6.29%
Short % of Float
of tradable shares sold short
31.1M
Shares Sold Short
-16.6% vs prior count
6.4 High
Days to Cover
trading days of normal volume to buy every short share back
4.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ELAN ranks across every disease it competes in
Competitive Position is a premium feature
See how ELAN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialELAN News
ELAN▲ +0.4%today
Elanco to Participate in UBS Global Healthcare Conference
Elanco Animal Health will attend the UBS Global Healthcare Conference on November 9, 2026. Executives Bob VanHimbergen and Bobby Modi will participate in a fireside chat at 1:15 p.m. EST. A live audio webcast will be accessible on Elanco's investor website, with a replay available afterward.
Read more →ELANElanco Animal Health Appoints Jamie Preston as Chief People Officer
Elanco Animal Health appointed Jamie Preston as Chief People Officer, effective November 3rd. She succeeds Dave Kinard, who will retire at year-end. Preston brings 23 years of HR experience from Eli Lilly, where she led global compensation and workforce innovation. Her appointment aims to enhance Elanco's workforce culture and innovation.
Read more →ELANElanco to Participate in BofA Securities Global Healthcare Conference 2026
Elanco Animal Health will attend the BofA Securities Global Healthcare Conference on September 22, 2026. CEO Jeff Simmons will participate in a fireside chat, which will be available via a live audio webcast. This event highlights Elanco's commitment to engaging with stakeholders and sharing insights into their innovative animal health solutions.
Read more →ELANExpanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Elanco Animal Health reported strong growth in its U.S. Pet Health business, driven by innovations in parasiticides and dermatology. The company anticipates high-single to low double-digit growth in the second half of 2026. As tick and allergy seasons expand, Elanco's market share and price gains are accelerating, reflecting robust demand from pet owners.
Read more →ELANElanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
Elanco Animal Health will announce its third quarter 2026 financial results on November 6, 2026. A conference call will follow at 8:00 a.m. ET to discuss the company's performance. Investors and the public can access the call via a live webcast on Elanco's website, with a replay available afterward.
Read more →ELANElanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Elanco Animal Health will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives, including CEO Jeff Simmons, will participate in a fireside chat. A live audio webcast will be available for interested stakeholders, with a replay accessible post-event.
Read more →ELANElanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
Elanco Animal Health has completed a 25,000-square-foot expansion of its Elwood, Kansas manufacturing site, enhancing its monoclonal antibody production capabilities. This expansion is crucial for meeting the rising demand for innovative pet health solutions, particularly the new anti-IL-31 mAb injection, Befrena. The investment aims to support Elanco's ambitious pipeline and strengthen its leadership in the biologics sector.
Read more →ELAN▼ -8.6%on this news
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Elanco received FDA Emergency Use Authorization for CLiK Extra, a topical spray to prevent New World screwworm infestations in livestock and wildlife. This product can be applied around wounds to protect various species, including sheep and cattle. Elanco emphasizes the importance of early intervention and monitoring to minimize risks associated with this parasite.
Read more →ELANElanco Animal Health Reports Second Quarter 2026 Results
Elanco Animal Health reported strong financial results for the second quarter of 2026, with revenue of $1.368 billion, reflecting a 10% increase year-over-year. The company raised its full-year revenue guidance to between $5.09 billion and $5.14 billion, driven by robust growth in both U.S. Pet Health and U.S. Farm Animal sectors. Adjusted EBITDA also saw a significant rise, indicating effective cost management and operational efficiency.
Read more →ELANElanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Elanco Animal Health has released its 2025 Impact Report, showcasing its commitment to animal health and societal needs. The report highlights significant achievements in innovation, sustainability, and community support. Key initiatives include revenue growth from new products, advancements in food safety, and employee engagement. Elanco aims to address pressing global challenges through its strategic focus on animal health.
Read more →ELANCredelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)
Elanco's Credelio Quattro has been shown to kill black-legged ticks within 8 hours and lone star ticks within 12 hours, outperforming competitors like Simparica Trio and NexGard Plus. The product maintains its effectiveness throughout the dosing period, crucial for preventing Lyme disease transmission. This data was published in the journal Parasites & Vectors.
Read more →ELANElanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
Elanco Animal Health will announce its second quarter 2026 financial results on August 5, 2026. A conference call will follow at 8:00 a.m. ET, allowing the investment community and media to discuss the company's performance. A live webcast will be available on Elanco's website, with a replay accessible afterward.
Read more →ELANElanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
Elanco Animal Health announced the launch of Elanco Ventures, a corporate venture capital platform with a $25 million commitment to foster innovation in animal health. The initiative will focus on investments in therapeutic advancements and supportive technologies, while also exploring opportunities within the One Health landscape. The platform is set to launch in late 2026 and will prioritize early-stage companies.
Read more →ELANElanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
Elanco Animal Health has received USDA approval for its TruCan Ultra Lyme-L4, a unique 1/2 mL combination vaccine for dogs that protects against Lyme disease and leptospirosis. This innovative product aims to provide effective protection while minimizing stress for animals during vaccination by requiring only one injection instead of two. The vaccine utilizes proprietary PureFil Technology to enhance safety, and its launch comes at a time when both diseases present significant risks to canine health across various geographic regions. Shipping is expected to commence within the next 30 days.
Read more →ELANElanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
Elanco Animal Health has announced its commitment to support U.S. livestock producers and pet owners following the first confirmed case of New World screwworm in Texas. The company is providing a range of treatment options and expert guidance to combat this significant threat to animal health and welfare. Elanco's portfolio includes products that have received Emergency Use Authorization from the FDA, ensuring effective management of infestations.
Read more →ELANNew Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
Elanco Animal Health's recent survey reveals that U.S. pet owners prioritize spending on their pets, with 91% maintaining or increasing their expenditure on pet health and wellness. Despite rising living costs, 90% of pet owners expect their spending to remain stable or increase. This trend indicates a robust commitment to pet care, positioning Elanco favorably in a growing animal health market projected to expand significantly in the coming years.
Read more →ELANElanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Elanco Animal Health has initiated the phased launch of Befrena (tirnovetmab), an anti-IL-31 monoclonal antibody designed to treat canine allergic and atopic dermatitis. Approved by the USDA in December 2025, Befrena aims to expand Elanco's portfolio within the $1.3 billion U.S. canine dermatology market. Initial reports from veterinarians participating in the Early Experience Program indicate positive outcomes for allergic dogs, with significant reductions in itching reported as early as 24 hours post-injection. This marks a significant milestone in Elanco’s commitment to animal health innovation.
Read more →ELANElanco to Participate in Upcoming Investor Conferences
Elanco Animal Health announced its participation in two upcoming investor conferences. CEO Jeff Simmons and CFO Bob VanHimbergen will engage in discussions at the Stifel 2026 Jaws & Paws Conference and the William Blair 46th Annual Growth Stock Conference. Live audio webcasts will be available for these events.
Read more →ELAN▲ +13.9%on this news
Elanco Animal Health Reports First Quarter 2026 Results
Elanco Animal Health reported first quarter revenue of $1,371 million, a 15 percent increase from the prior year. Adjusted earnings per share reached $0.40, while adjusted EBITDA totaled $334 million. The company raised its full year revenue guidance to between $5,010 million and $5,085 million. Management also improved the year end net leverage ratio target to between 3.0x and 3.2x.
Read more →ELANElanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock
Elanco Animal Health has received Emergency Use Authorization from the FDA for its Negasunt Powder and a Section 18 Emergency Exemption for Tanidil to combat New World screwworm infestations in livestock. These measures are proactive, ensuring veterinarians and livestock producers have effective treatment options as the threat of screwworms approaches the U.S. border. Elanco emphasizes the importance of education and monitoring for early detection and intervention.
Read more →About Elanco Animal Health Incorporated
Headquarters450 ELANCO CIRCLE, INDIANAPOLIS, IN, 46221
BIOPHARMAWATCH ELITE PLUS
Trade the next ELAN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime